// App-Quantinova.ai

: A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).

Researchers

Presenter

  • Maha H. A. Hussain

Principal Investigators

  • Masha Kocherginsky

  • Parminder Singh

  • Zin Myint

  • Di Maria Jiang

  • Elizabeth Marie Wulff-Burchfield

  • Elad Sharon

  • Richard Piekarz

  • Joshua J Meeks

  • David James VanderWeele

Medical Centers

  • University of Kentucky, Lexington, KY

  • Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  • Cancer Therapy Evaluation Program, Division of Cancer Treatment & Diagnosis, National Cancer Institute of the National Institutes of Health, Bethesda, MD

  • Mayo Clinic, Phoenix, AZ

  • University of Kansas Medical Center Department of Internal Medicine, Westwood, KS

  • Northwestern University, Chicago, IL

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • T-cell receptor

Drug/Treatment

  • Pembrolizumab

  • Tazemetostat

  • Cisplatin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT03854474

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved